
DBD Stock Forecast & Price Target
DBD Analyst Ratings
Bulls say
Diebold Nixdorf has demonstrated strong growth in its Retail segment, with revenues of $255 million, reflecting an 8.1% quarter-over-quarter increase and a 7.8% year-over-year increase, while gross margins expanded by 100 basis points to 24.7%. The company is on track to achieve free cash flow in the range of $190 million to $210 million by 2025, up from $109 million in 2024, alongside consistent positive free cash flow generation for four consecutive quarters. With anticipated robust year-over-year EPS growth in 2026 and planned margin expansions, Diebold Nixdorf is well-positioned for ongoing financial improvement and investor interest.
Bears say
Diebold Nixdorf Inc faces a negative outlook due to several fundamental challenges, including technological missteps and failure to innovate, potentially resulting in declining revenues and profitability. The Banking segment's gross margins have shown a slight decline quarter-over-quarter, indicating increased pricing pressure and heightened competition, which could adversely affect the company's financial stability. Additionally, the reliance on cost-saving measures and management's anticipated operational expenditure reductions may not sufficiently address ongoing risks such as tariff impacts, supply chain disruptions, and currency volatility, further complicating the company's financial outlook.
This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.
DBD Analyst Forecast & Price Prediction
Start investing in DBD
Order type
Buy in
Order amount
Est. shares
0 shares